Ticagrelor De-escalation Strategy in East Asian Patients With AMI
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
Ticagrelor as nonthienopyridine, direct-acting P2Y12 receptor antagonist, had significantly
greater platelet inhibition, which could reduce ischemic events at acute phase, however,
resulting in more incidence of bleedings than pro-drug P2Y12 receptor inhibitor during
chronic phase for management of acute myocardial infarction (AMI) following percutaneous
coronary intervention (PCI). Also, East Asians have higher response to potent agent, like
ticagrelor, when compared with Caucasians. With this in mind, East Asian patients will be
required optimal, potentially reduced dose of ticagrelor to improve the safety profile,
maintaining better vascular outcomes. Similarly, there are insufficient East Asian data on
the efficacy and safety of low-dose ticagrelor in real-word practice. Whether the
de-escalation strategy (ticagrelor 60/45 mg twice daily) are more adequate for clinical
practice in East Asian is unclear. Therefore, the investigators design the EASTYLE study,
hypothesis that low-dose ticagrelor would be more likely adequate for optimal antiplatelet
treatment without increasing ischemic and bleeding events in East Asian with AMI compared
with standard-dose ticagrelor. In the EASTYLE trial, further clinical data of de-escalation
strategy guided AMI management in East Asian will be provided.